Oxaliplatin Related LncRNAs Prognostic Models Predict the Prognosis of Patients Given Oxaliplatin-based Chemotherapy

Overview

Journal Cancer Cell Int

Publisher Biomed Central

Date 2023 May 27

PMID 37245016

Authors

Qing-Nan Zhou

Rong-E Lei

Yun-Xiao Liang

Si-Qi Li

Xian-Wen Guo

Bang-Li Hu

Affiliations

Soon will be listed here.

Abstract

Background: Oxaliplatin-based chemotherapy is the first-line treatment for colorectal cancer (CRC). Long noncoding RNAs (lncRNAs) have been implicated in chemotherapy sensitivity. This study aimed to identify lncRNAs related to oxaliplatin sensitivity and predict the prognosis of CRC patients underwent oxaliplatin-based chemotherapy.

Methods: Data from the Genomics of Drug Sensitivity in Cancer (GDSC) was used to screen for lncRNAs related to oxaliplatin sensitivity. Four machine learning algorithms (LASSO, Decision tree, Random-forest, and support vector machine) were applied to identify the key lncRNAs. A predictive model for oxaliplatin sensitivity and a prognostic model based on key lncRNAs were established. The published datasets, and cell experiments were used to verify the predictive value.

Results: A total of 805 tumor cell lines from GDSC were divided into oxaliplatin sensitive (top 1/3) and resistant (bottom 1/3) groups based on their IC50 values, and 113 lncRNAs, which were differentially expressed between the two groups, were selected and incorporated into four machine learning algorithms, and seven key lncRNAs were identified. The predictive model exhibited good predictions for oxaliplatin sensitivity. The prognostic model exhibited high performance in patients with CRC who underwent oxaliplatin-based chemotherapies. Four lncRNAs, including C20orf197, UCA1, MIR17HG, and MIR22HG, displayed consistent responses to oxaliplatin treatment in the validation analysis.

Conclusion: Certain lncRNAs were associated with oxaliplatin sensitivity and predicted the response to oxaliplatin treatment. The prognostic models established based on the key lncRNAs could predict the prognosis of patients given oxaliplatin-based chemotherapy.

Citing Articles

Multi-Omics Mining of lncRNAs with Biological and Clinical Relevance in Cancer.

Salido-Guadarrama I, Romero-Cordoba S, Rueda-Zarazua B Int J Mol Sci. 2023; 24(23).

PMID: 38068923 PMC: 10706612. DOI: 10.3390/ijms242316600.

References

Sun F, Liang W, Qian J . The identification of CRNDE, H19, UCA1 and HOTAIR as the key lncRNAs involved in oxaliplatin or irinotecan resistance in the chemotherapy of colorectal cancer based on integrative bioinformatics analysis. Mol Med Rep. 2019; 20(4):3583-3596. PMC: 6755158. DOI: 10.3892/mmr.2019.10588. View

Li S, Yu W, Xie F, Luo H, Liu Z, Lv W . Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer. Nat Commun. 2023; 14(1):8. PMC: 9810618. DOI: 10.1038/s41467-022-35431-x. View

Yang W, Lu S, Peng L, Zhang Z, Zhang Y, Guo D . Integrated analysis of necroptosis-related genes for evaluating immune infiltration and colon cancer prognosis. Front Immunol. 2023; 13:1085038. PMC: 9814966. DOI: 10.3389/fimmu.2022.1085038. View

Chen L, Zhang Y, Pan X, Liu M, Wang S, Huang T . Tissue Expression Difference between mRNAs and lncRNAs. Int J Mol Sci. 2018; 19(11). PMC: 6274976. DOI: 10.3390/ijms19113416. View

Zhao S, Guan B, Mi Y, Shi D, Wei P, Gu Y . LncRNA MIR17HG promotes colorectal cancer liver metastasis by mediating a glycolysis-associated positive feedback circuit. Oncogene. 2021; 40(28):4709-4724. PMC: 8282501. DOI: 10.1038/s41388-021-01859-6. View

Cocetta V, Tinazzi M, Giacomini I, Rosato B, Ragazzi E, Berretta M . Clinical Evidence of Interaction between Nutraceutical Supplementation and Platinum-based Chemotherapy. Curr Med Chem. 2022; 30(19):2141-2164. DOI: 10.2174/0929867329666220527120237. View

Raez L, Santos E, Webb R, Wade J, Brito R, Karr M . A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC). Cancer Chemother Pharmacol. 2013; 72(5):1103-10. DOI: 10.1007/s00280-013-2301-z. View

Kang X, Huo Y, Jia S, He F, Li H, Zhou Q . Silenced LINC01134 Enhances Oxaliplatin Sensitivity by Facilitating Ferroptosis Through GPX4 in Hepatocarcinoma. Front Oncol. 2022; 12:939605. PMC: 9304856. DOI: 10.3389/fonc.2022.939605. View

Dardare J, Witz A, Betz M, Francois A, Meras M, Lamy L . DDB2 represses epithelial-to-mesenchymal transition and sensitizes pancreatic ductal adenocarcinoma cells to chemotherapy. Front Oncol. 2022; 12:1052163. PMC: 9773984. DOI: 10.3389/fonc.2022.1052163. View

10.

Yao J, Chen X, Liu X, Li R, Zhou X, Qu Y . Characterization of a ferroptosis and iron-metabolism related lncRNA signature in lung adenocarcinoma. Cancer Cell Int. 2021; 21(1):340. PMC: 8254945. DOI: 10.1186/s12935-021-02027-2. View

11.

Martinez-Balibrea E, Martinez-Cardus A, Gines A, Ruiz de Porras V, Moutinho C, Layos L . Tumor-Related Molecular Mechanisms of Oxaliplatin Resistance. Mol Cancer Ther. 2015; 14(8):1767-76. DOI: 10.1158/1535-7163.MCT-14-0636. View

12.

Hou M, Li C, Dong S . LINC00963/miR-4458 regulates the effect of oxaliplatin in gastric cancer by mediating autophagic flux through targeting of ATG16L1. Sci Rep. 2021; 11(1):20951. PMC: 8546147. DOI: 10.1038/s41598-021-98728-9. View

13.

Lin J, Xia L, Oyang L, Liang J, Tan S, Wu N . The POU2F1-ALDOA axis promotes the proliferation and chemoresistance of colon cancer cells by enhancing glycolysis and the pentose phosphate pathway activity. Oncogene. 2022; 41(7):1024-1039. PMC: 8837540. DOI: 10.1038/s41388-021-02148-y. View

14.

Zhang Y, Zhuang T, Xin Z, Sun C, Li D, Ma N . Construction of a Necroptosis-Related lncRNA Signature for Predicting Prognosis and Immune Response in Kidney Renal Clear Cell Carcinoma. Cells. 2023; 12(1). PMC: 9818734. DOI: 10.3390/cells12010066. View

15.

Yi Y, Li L, Song F, Li P, Chen M, Ni S . L-tetrahydropalmatine reduces oxaliplatin accumulation in the dorsal root ganglion and mitochondria through selectively inhibiting the transporter-mediated uptake thereby attenuates peripheral neurotoxicity. Toxicology. 2021; 459:152853. DOI: 10.1016/j.tox.2021.152853. View

16.

Lai J, Chen W, Zhao A, Huang J . Determination of a DNA repair-related gene signature with potential implications for prognosis and therapeutic response in pancreatic adenocarcinoma. Front Oncol. 2022; 12:939891. PMC: 9638008. DOI: 10.3389/fonc.2022.939891. View

17.

Wang S, Li J, Yang X . Long Non-Coding RNA LINC00525 Promotes the Stemness and Chemoresistance of Colorectal Cancer by Targeting miR-507/ELK3 Axis. Int J Stem Cells. 2019; 12(2):347-359. PMC: 6657946. DOI: 10.15283/ijsc19041. View

18.

Yuan J, Tan L, Yin Z, Zhu W, Tao K, Wang G . MIR17HG-miR-18a/19a axis, regulated by interferon regulatory factor-1, promotes gastric cancer metastasis via Wnt/β-catenin signalling. Cell Death Dis. 2019; 10(6):454. PMC: 6560107. DOI: 10.1038/s41419-019-1685-z. View

19.

Yang W, Soares J, Greninger P, Edelman E, Lightfoot H, Forbes S . Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2012; 41(Database issue):D955-61. PMC: 3531057. DOI: 10.1093/nar/gks1111. View

20.

Zhang L, Li C, Su X . Emerging impact of the long noncoding RNA MIR22HG on proliferation and apoptosis in multiple human cancers. J Exp Clin Cancer Res. 2020; 39(1):271. PMC: 7712612. DOI: 10.1186/s13046-020-01784-8. View